However, in that study, patients with HER2 + breast cancers were randomly assigned to different NACT groups without HER2-targeted therapy, and the yeast assay was used to assess TP53 mutations which does not distinguish between pure loss-of-function mutations compared to mutations with simultaneous gain and loss-of-function [31, 32]. The gene discussed is ERBB2; the disease is breast cancer.